Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations.
The drugmaker said clinical-trial data suggested the medicine, emugrobart, wouldn’t hit internal targets.
Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary .
Blockbuster GLP-1 drugs have transformed the lives of millions of people.
A new obesity drug from pharma giant Novo Nordisk has been shown to lead to greater weight loss than a popular competitor medication, new research shows.
Physical inactivity is the single strongest predictor of obesity across US counties, according to a new AI-driven analysis explaining 78% of the variation in county-level obesity prevalence.
New Lancet Diabetes and Endocrinology Commission criteria, which distinguish clinical obesity from preclinical obesity, may better inform patient selection and risk assessment for bariatric surgery .
In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with dueling datasets on oral and injectable GLP-1s.
Uncover the latest and most impactful research in Sleep Quality and Obesity Interactions.
A new report from the nonprofit Trust for America’s Health shows obesity rates among adults in Georgia are stabilizing but still too high.